Will Cerner (CERN) Stock Be Helped By This Analyst Upgrade?

NEW YORK (TheStreet) -- Shares of Cerner Corp  (CERN) are up 1.29% to $55.04 after the healthcare company was upgraded to "outperform" from "market perform" at Wells Fargo (WFC).

The firm cited the company's acquisition of the Siemens (SIEGY) healthcare IT business, and raised its price target range on the shares to $65 to $70 from $55 to $60.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Separately, TheStreet Ratings team rates CERNER CORP as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate CERNER CORP (CERN) a BUY. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • CERN's revenue growth has slightly outpaced the industry average of 15.9%. Since the same quarter one year prior, revenues rose by 20.4%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • CERN's debt-to-equity ratio is very low at 0.05 and is currently below that of the industry average, implying that there has been very successful management of debt levels. To add to this, CERN has a quick ratio of 2.38, which demonstrates the ability of the company to cover short-term liquidity needs.
  • The stock has risen over the past year as investors have generally rewarded the company for its earnings growth and other positive factors like the ones we have cited in this report. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Health Care Technology industry average. The net income increased by 14.3% when compared to the same quarter one year prior, going from $112.91 million to $129.03 million.
  • You can view the full analysis from the report here: CERN Ratings Report
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Cognizant Technology, Advanced Micro Devices: 'Mad Money' Lightning Round

Play Defense, Play the Dollar: Cramer's 'Mad Money' Recap (Tuesday 8/29/17)

These Stocks Are Ready to Reverse Course

Wall Street Weighs In on Athenahealth's Strategic Options

Trader's Daily Notebook: Staying on the Sidelines?